Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases

Imagem de Miniatura
Arquivos
art_AIKAWA_Increment_of_immunogenicity_after_third_dose_of_a_2022.PDF (603.41 KB)
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMJ PUBLISHING GROUP
Autores
Citação
ANNALS OF THE RHEUMATIC DISEASES, v.81, n.7, p.1036-1043, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective To determine the immunogenicity of the third dose of CoronaVac vaccine in a large population of patients with autoimmune rheumatic diseases (ARD) and the factors associated with impaired response. Methods Adult patients with ARD and age-balanced/sex-balanced controls (control group, CG) previously vaccinated with two doses of CoronaVac received the third dose at D210 (6 months after the second dose). The presence of anti-SARS-CoV-2 S1/S2 IgG and neutralising antibodies (NAb) was evaluated previously to vaccination (D210) and 30 days later (D240). Patients with controlled disease suspended mycophenolate mofetil (MMF) for 7 days or methotrexate (MTX) for 2 weekly doses after vaccination. Results ARD (n=597) and CG (n=199) had comparable age (p=0.943). Anti-S1/S2 IgG seropositivity rates significantly increased from D210 (60%) to D240 (93%) (p<0.0001) in patients with ARD. NAb positivity also increased: 38% (D210) vs 81.4% (D240) (p<0.0001). The same pattern was observed for CG, with significantly higher frequencies for both parameters at D240 (p<0.05). Multivariate logistic regression analyses in the ARD group revealed that older age (OR=0.98, 95% CI 0.96 to 1.0, p=0.024), vasculitis diagnosis (OR=0.24, 95% CI 0.11 to 0.53, p<0.001), prednisone >= 5 mg/day (OR=0.46, 95% CI 0.27 to 0.77, p=0.003), MMF (OR=0.30, 95% CI 0.15 to 0.61, p<0.001) and biologics (OR=0.27, 95% CI 0.16 to 0.46, p<0.001) were associated with reduced anti-S1/S2 IgG positivity. Similar analyses demonstrated that prednisone >= 5 mg/day (OR=0.63, 95% CI 0.44 to 0.90, p=0.011), abatacept (OR=0.39, 95% CI 0.20 to 0.74, p=0.004), belimumab (OR=0.29, 95% CI 0.13 to 0.67, p=0.004) and rituximab (OR=0.11, 95% CI 0.04 to 0.30, p<0.001) were negatively associated with NAb positivity. Further evaluation of COVID-19 seronegative ARD at D210 demonstrated prominent increases in positivity rates at D240 for anti-S1/S2 IgG (80.5%) and NAb (59.1%) (p<0.0001). Conclusions We provide novel data on a robust response to the third dose of CoronaVac in patients with ARD, even in those with prevaccination COVID-19 seronegative status. Drugs implicated in reducing immunogenicity after the regular two-dose regimen were associated with non-responsiveness after the third dose, except for MTX.
Palavras-chave
COVID-19, autoimmune diseases, vaccination, biological therapy, therapeutics
URI
https://observatorio.fm.usp.br/handle/OPI/48669
Referências
  1. Aikawa NE, 2022, LANCET RHEUMATOL, V4, pE113, DOI 10.1016/S2665-9913(21)00327-1
  2. AREND WP, 1990, ARTHRITIS RHEUM, V33, P1129
  3. Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255
  4. Barda N, 2021, LANCET, V398, P2093, DOI 10.1016/S0140-6736(21)02249-2
  5. Ben David SS, 2021, CLIN IMMUNOL, V232, DOI 10.1016/j.clim.2021.108860
  6. Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339
  7. Bensouna I, 2022, AM J KIDNEY DIS, V79, P185, DOI 10.1053/j.ajkd.2021.08.005
  8. Bertoglio IM, 2021, ACR OPEN RHEUMATOL, V3, P804, DOI 10.1002/acr2.11329
  9. Bertrand D, 2021, KIDNEY INT, V100, P1337, DOI 10.1016/j.kint.2021.09.014
  10. Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2
  11. Chia Wan Ni, 2021, Lancet Microbe, V2, pe240, DOI 10.1016/S2666-5247(21)00025-2
  12. Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, P1093, DOI 10.1002/art.41734
  13. Dougherty K, 2021, MMWR-MORBID MORTAL W, V70, DOI 10.15585/mmwr.mm7028e2
  14. Embi PJ, 2021, MMWR-MORBID MORTAL W, V70, P1553, DOI 10.15585/mmwr.mm7044e3
  15. Espi M., 2021, JUSTIFICATION SAFETY
  16. Flaxman A, 2021, LANCET, V398, P981, DOI 10.1016/S0140-6736(21)01699-8
  17. Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462
  18. Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715
  19. Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861
  20. KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
  21. Karaba Andrew H, 2022, Am J Transplant, V22, P1253, DOI [10.1101/2021.08.11.21261914, 10.1111/ajt.16933]
  22. Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8
  23. Le Bourgeois A, 2022, BRIT J HAEMATOL, V196, pE38, DOI 10.1111/bjh.17911
  24. LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807
  25. Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583
  26. Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468
  27. Marlet J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101055
  28. Mbaeyi S., 2021, MORBIDITY MORTALITY, V2021
  29. Medeiros-Ribeiro AC, 2021, NAT MED, V27, P1744, DOI 10.1038/s41591-021-01469-5
  30. Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
  31. Chau NVV, 2021, ECLINICALMEDICINE, V41, DOI 10.1016/j.eclinm.2021.101143
  32. Pablos JL, 2020, ANN RHEUM DIS, V79, P1544, DOI 10.1136/annrheumdis-2020-218296
  33. Peled Y, 2022, J HEART LUNG TRANSPL, V41, P148, DOI 10.1016/j.healun.2021.08.010
  34. Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473
  35. Araujo CSR, 2022, ANN RHEUM DIS, V81, P889, DOI 10.1136/annrheumdis-2021-221916
  36. Robert T, 2022, NEPHROL DIAL TRANSPL, V37, P390, DOI 10.1093/ndt/gfab299
  37. Rosenberg Eli S, 2021, MMWR Morb Mortal Wkly Rep, V70, P1150, DOI 10.15585/mmwr.mm7034e1
  38. Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233
  39. Schmiedeberg K, 2022, LANCET RHEUMATOL, V4, pE11, DOI 10.1016/S2665-9913(21)00328-3
  40. Shitrit P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.39.2100822
  41. Shroff RT, 2021, NAT MED, V27, P2002, DOI 10.1038/s41591-021-01542-z
  42. Silva CA., 2021, ANTI SARS COV 2 IMMU
  43. Subramanian SV, 2021, EUR J EPIDEMIOL, V36, P1237, DOI 10.1007/s10654-021-00808-7
  44. Taylor SC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02438-20
  45. Tillett W, 2012, J RHEUMATOL, V39, P154, DOI 10.3899/jrheum.110845
  46. van den Hoogen F, 2013, ANN RHEUM DIS, V72, P1747, DOI [10.1002/art.38098, 10.1136/annrheumdis-2013-204424]
  47. Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554
  48. Werbel WA, 2021, ANN INTERN MED, V174, P1330, DOI 10.7326/L21-0282
  49. Yue L, 2021, EMERG MICROBES INFEC, V10, P2125, DOI 10.1080/22221751.2021.1996210
  50. Zeng G, 2022, LANCET INFECT DIS, V22, P483, DOI 10.1016/S1473-3099(21)00681-2

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - FM/MPT
Carregar mais